Table 2.

Selective inhibitor combination sensitivities by feature among AML and CLL patient samples surveyed

Feature type	Diagnosis category	Combination	IC50		AUC
			Median CR	P value*	Median CR	P value*
Mutation
DNMT3A	AML	JQ1/palbociclib	0.1187	0.0171	0.5693	0.0189
NPM1	AML	JQ1/palbociclib	0.1138	0.0045	0.6830	0.0120
NPM1	AML	JQ1/sorafenib	0.4375	0.0108	0.6952	0.0091
Cytogenetics
Complex karyotype	AML	Idelalisib/quizartinib	0.1753	0.0227	0.6872	0.0078
Normal karyotype	AML	Ruxolitinib/cabozantinib	0.3289	0.0126	0.8040	0.0015
Normal karyotype	AML	JQ1/sorafenib	0.4375	0.0378	0.8495	0.0197
del(13q)	CLL	Trametinib/palbociclib	0.1161	0.0057	0.4121	<0.0001
del(13q)	CLL	Venetoclax/palbociclib	0.2673	0.0013	0.5269	<0.0001
Surface antigen
CD11b	AML	Venetoclax/doramapimod	0.0441	0.0136	0.4503	0.0185
CD11b	AML	Venetoclax/JQ1	0.1205	0.0014	0.2539	0.0070
CD14	AML	Venetoclax/JQ1	0.1004	0.0201	0.2539	0.0061
CD15	AML	Venetoclax/idelalisib	0.0308	0.0189	0.6769	0.0309
CD58	AML	Venetoclax / ARRY-382	0.0381	0.0012	0.2796	0.0006
CD58	AML	Venetoclax/dasatinib	0.0229	0.0007	0.2594	0.0021
CD58	AML	Venetoclax/doramapimod	0.0402	0.0031	0.4396	0.0035
CD58	AML	Venetoclax/ruxolitinib	0.0027	0.0036	0.3359	0.0053

^*P values are FDR-adjusted.